Novo Nordisk will work with some of the telehealth companies that sold knock-off versions of obesity drugs like its popular medicine Wegovy,

诺和诺德将与一些销售其热门药物Wegovy等减肥药仿制品的远程医疗公司合作，

announcing Tuesday

周二宣布

deals with Hims & Hers, LifeMD and Ro to sell branded Wegovy distributed through the Danish drugmaker’s direct-to-consumer pharmacy.

与Hims & Hers、LifeMD和Ro达成协议，销售通过丹麦制药商直接面向消费者的药店分销的Wegovy品牌药物。

The announcement comes days after a federal court in Texas

该公告发布于德克萨斯州联邦法院做出判决的数天后

rejected a legal challenge

驳回了一项法律挑战

by compounding pharmacies to the Food and Drug Administration’s recent determination that Wegovy was no longer in shortage. As long as semaglutide, the active ingredient in Wegovy and the diabetes drug Ozempic, remained in short supply, compounding pharmacies could manufacture and distribute copycat versions..

复合药店向食品和药物管理局最近的决定，即Wegovy不再短缺。只要Wegovy和糖尿病药物Ozempic中的活性成分司美格鲁肽仍然供不应求，复合药店就可以生产和分销仿制版本。

The telehealth companies will be able to sell Wegovy distributed through the NovoCare Pharmacy — which the

远程医疗公司将能够销售通过诺和护理药房分销的Wegovy——这

drugmaker started in March

制药商三月开始

— to people who are prescribed the obesity shot but don’t use insurance to cover the cost. Two of the telehealth companies,

—— 给那些被处方了肥胖症注射剂但没有使用保险来支付费用的人。两家远程医疗公司，

LifeMD

生命医学

and

和

Ro

罗马尼亚语

, will sell Wegovy at the same $499 price as NovoCare, while

，将以与NovoCare相同的价格499美元销售Wegovy，而

Hims will offer

Hims 将提供

it at $599 per month.

每月599美元。

“We believe patients living with this chronic disease who want and need treatment under the care of a licensed healthcare professional, including those embracing the growing telehealth community, deserve to get the real thing,' said Dave Moore, Novo’s head of U.S. operations, in a statement.

“我们相信，患有这种慢性病的患者，如果他们希望并在持照医疗专业人员的护理下需要治疗，包括那些接受不断发展的远程医疗社区的人，都应该得到真正的治疗，”诺和美国业务主管戴夫·摩尔在一份声明中表示。

The deals come as Novo is facing a growing threat to its $8.4 billion obesity blockbuster from Eli Lilly, which was first to establish its own

这些交易达成之际，诺和正面临来自礼来日益增长的威胁，礼来是首个推出自己价值84亿美元的肥胖症重磅药物的公司。

direct-to-consumer channel

直销渠道

for obesity drugs. Lilly’s rival drug, Zepbound, proved in testing that it could help people with obesity

用于治疗肥胖症的药物。礼来公司的竞争药物Zepbound在测试中证明可以帮助肥胖人群

lose more weight

减掉更多体重

than Wegovy, which some analysts think should give it an edge in marketing.

比Wegovy更具优势，一些分析师认为这应该会使其在营销方面占据上风。

Novo’s deal with the telehealth companies could expand Wegovy’s reach among people paying out of pocket, following Lilly’s similar deals with

诺和与远程医疗公司的交易可能会扩大Wegovy在自费人群中的覆盖范围，类似于礼来公司之前的交易。

LifeMD

生命医学

and

和

Ro

罗马尼亚语

. Wegovy still retains some advantages, however, including being the only obesity drug shown to

. 然而，Wegovy 仍然保留了一些优势，包括是唯一被证明能够

prevent cardiovascular complications and death

预防心血管并发症和死亡

, which has opened the door to limited Medicare coverage.

，这为有限的联邦医疗保险覆盖打开了大门。

Moreover, the race is on to launch an oral obesity drug. Novo recently said it has asked the FDA to approve an

此外，推出口服减肥药的竞赛已经开始。诺和最近表示，它已要求美国食品药品监督管理局批准一种

oral version of semaglutide

口服版本的司美鲁肽

that completed pivotal trials in obesity. Lilly is

在肥胖症方面完成了关键试验。礼来公司是

close behind

紧随其后

, with a pill that may be easier to manufacture. That could give Lilly an edge as both companies have struggled to expand manufacturing to keep up with patient demand, a factor that had led to the shortages.

，这种药片可能更容易生产。这可能会使礼来公司占据优势，因为两家公司都在努力扩大生产以满足患者需求，这也是导致药品短缺的一个因素。

Novo’s shares rose 4% in morning trading, while Hims shares were up more than 20% and LifeMD by nearly 30%.

诺沃的股价在早盘交易中上涨了4%，而Hims的股价上涨了20%以上，LifeMD的股价上涨了近30%。